NEW YORK, June 29, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action lawsuit on behalf of all purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 5, 2024. To join the Altimmune class action, go to https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq. tol ...

文章核心观点 - 阿尔泰默恩(Altimmune)正在研发一种新的减肥药物pemvidutide,该药物在临床试验中显示出较好的减肥效果,且主要减掉脂肪而非肌肉,这可能成为目前市场上主导的减肥药物Wegovy的潜在竞争对手 [1][4][5][7] - 阿尔泰默恩目前现金充足,研发支出较低,在获得监管批准前有较长的运营周期 [8][9] - 尽管存在一定风险,但阿尔泰默恩的减肥药物候选药物有望在未来成为一个更有利于某些人群(如老年人)的选择 [13][14] 公司概况 - 阿尔泰默恩是一家小型生物科技公司,目前有两个处于II期临床试验阶段的项目,都在研究同一种分子pemvidutide [3] - 其中针对肥胖症的项目是对抗Wegovy的潜在竞争对手 [4] - 公司目前现金储备充足,研发支出较低,在获得监管批准前有较长的运营周期 [8][9] 行业概况 - 减肥药物市场竞争激烈,由诺和诺德(Novo Nordisk)的Wegovy和Ozempic等药物主导 [1][14] - 阿尔泰默恩的新药如果获批上市,将需要与诺和诺德、礼来(Eli Lilly)等大型制药公司展开竞争 [14]

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”), of the important July 5, 2024 lead plaintiff deadline. SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

NEW YORK, June 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=87822&from=4 CLASS PERIOD: December 1, 2023 to Ap ...

pidjoe/E+ via Getty Images The small biotech sector has underperformed the major indices in a major way so far in 2024. While the NASDAQ (COMP.IND) and S&P 500 (SP500) are both up in the mid-teens so far this year, the SPDR® S&P Biotech ETF (XBI) up just over three percent in 2024. It should be noted that AI juggernaut Nvidia Corporation (NVDA) has accounted for approximately a third of the gains in the major indices year to date. Seeking Alpha The small biotech arena should perform better as the Federal Re ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 investing in Altimmune stock or options between December 1, 2023 and April 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www ...

GAITHERSBURG, Md., June 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that Richard Eisenstadt, the Company's Chief Financial Officer, passed away unexpectedly on Monday, June 24, 2024. "We are all shocked and saddened by Rich's passing. On behalf of everyone at Altimmune, I extend our heartfelt condolences to his family during this difficult time," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "Rich was ...

GAITHERSBURG, Md., June 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that Richard Eisenstadt, the Company's Chief Financial Officer, passed away unexpectedly on Monday, June 24, 2024. "We are all shocked and saddened by Rich's passing. On behalf of everyone at Altimmune, I extend our heartfelt condolences to his family during this difficult time," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "Rich was ...

NEW YORK, June 25, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=87109&from=4 CLASS PERIOD: December 1, 2023 to Ap ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) investors that a class action has been filed on behalf of investors. Altimmune investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw ...